Epigenetic therapy and clinical trials

Section information

Section edited by Richard Momparler and Nick La Thangue  
This section publishes research on the potential of epigenetic agents for the treatment of diseases. Manuscripts on both preclinical and early clinical studies are welcome. Preclinical studies should include the rationale for translation of the activity of epigenetic agents from the bench to the bedside. The clinical trials on epigenetic agents should include the background, rationale, clinical design and key endpoints. 

  1. Review

    Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

    Multiple myeloma (MM) is a hematological malignancy, which remains incurable because most patients eventually relapse or become refractory to current treatments. Due to heterogeneity within the cancer cell mic...

    Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, Claudina Perez-Novo, Wim Vanden Berghe and Muriel Cuendet

    Clinical Epigenetics 2017 9:17

    Published on: 10 February 2017

  2. Research

    Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

    Refractory and/or relapsed diffuse large B cell lymphoma (RR-DLBCL) patients are incurable with conventional chemotherapy due to the aggressiveness and the chemorefractory state of these tumors. DNA hypermethy...

    Benet Pera, Tiffany Tang, Rossella Marullo, Shao-Ning Yang, Haelee Ahn, Jayeshkumar Patel, Rebecca Elstrom, Jia Ruan, Richard Furman, John Leonard, Leandro Cerchietti and Peter Martin

    Clinical Epigenetics 2016 8:79

    Published on: 22 July 2016

  3. Review

    Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials

    Aberrant DNA methylation has been identified as a key molecular event regulating the pathogenesis of myelodysplastic syndromes (MDS); myeloid neoplasms with an inherent risk of transformation to acute myeloid ...

    Seongseok Yun, Nicole D. Vincelette, Ivo Abraham, Keith D. Robertson, Martin E. Fernandez-Zapico and Mrinal M. Patnaik

    Clinical Epigenetics 2016 8:68

    Published on: 14 June 2016

  4. Research

    Ultraviolet-B induces ERCC6 repression in lens epithelium cells of age-related nuclear cataract through coordinated DNA hypermethylation and histone deacetylation

    Ultraviolet-B (UVB) exposure attributes to the formation of age-related nuclear cataract (ARNC), which is mediated with DNA damage. DNA damage, an important factor for pathogenesis of ARNC, is induced by UVB, ...

    Yong Wang, Fei Li, Guowei Zhang, Lihua Kang and Huaijin Guan

    Clinical Epigenetics 2016 8:62

    Published on: 26 May 2016

  5. Review

    Sirtuin functions and modulation: from chemistry to the clinic

    Sirtuins are NAD+-dependent histone deacetylases regulating important metabolic pathways in prokaryotes and eukaryotes and are involved in many biological processes such as cell survival, senescence, proliferatio...

    Vincenzo Carafa, Dante Rotili, Mariantonietta Forgione, Francesca Cuomo, Enrica Serretiello, Gebremedhin Solomon Hailu, Elina Jarho, Maija Lahtela-Kakkonen, Antonello Mai and Lucia Altucci

    Clinical Epigenetics 2016 8:61

    Published on: 25 May 2016

  6. Review

    Epigenetic treatment of solid tumours: a review of clinical trials

    Epigenetic treatment has been approved by regulatory agencies for haematological malignancies. The success observed in cutaneous lymphomas represents a proof of principle that similar results may be obtained i...

    Clara Nervi, Elisabetta De Marinis and Giovanni Codacci-Pisanelli

    Clinical Epigenetics 2015 7:127

    Published on: 10 December 2015

  7. Research

    Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors (HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer’s disease (AD). Howev...

    M. Cuadrado-Tejedor, C. Garcia-Barroso, J. Sanzhez-Arias, S. Mederos, O. Rabal, A. Ugarte, R. Franco, M. Pascual-Lucas, V. Segura, G. Perea, J. Oyarzabal and A. Garcia-Osta

    Clinical Epigenetics 2015 7:108

    Published on: 8 October 2015

Advertisement